CATALOGO DEI PRODOTTI DELLA RICERCA

Caminati, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.347
EU - Europa 1.803
AS - Asia 1.098
AF - Africa 5
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 5.262
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.338
CN - Cina 817
IT - Italia 437
IE - Irlanda 286
FR - Francia 279
GB - Regno Unito 263
SE - Svezia 238
DE - Germania 165
SG - Singapore 157
FI - Finlandia 58
VN - Vietnam 49
JP - Giappone 27
BE - Belgio 16
UA - Ucraina 16
HK - Hong Kong 14
RU - Federazione Russa 11
IN - India 9
KR - Corea 9
TR - Turchia 9
ES - Italia 7
NL - Olanda 6
CA - Canada 5
AT - Austria 4
BG - Bulgaria 3
CH - Svizzera 3
LV - Lettonia 3
MX - Messico 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
CL - Cile 2
EG - Egitto 2
EU - Europa 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MD - Moldavia 1
NO - Norvegia 1
PE - Perù 1
PL - Polonia 1
SC - Seychelles 1
TH - Thailandia 1
Totale 5.262
Salva come PNG Salva come JPEG
Città #
Chandler 603
Dublin 282
New York 248
Southend 245
Beijing 225
Ashburn 139
Lawrence 120
Princeton 120
Sindelfingen 102
Singapore 97
Wilmington 95
Verona 93
Jacksonville 81
Jinan 62
Ann Arbor 56
Nanjing 47
Hebei 46
Woodbridge 46
Shenyang 44
Helsinki 41
Redwood City 41
Redmond 40
Guangzhou 30
Dong Ket 29
Zhengzhou 29
Boardman 28
Haikou 26
Ningbo 24
Bologna 22
Norwalk 21
Kent 20
Rome 20
Seattle 20
Tokyo 19
Changsha 18
Milan 18
Taiyuan 17
Taizhou 16
Tianjin 16
Houston 15
Hangzhou 14
Brussels 13
Nanchang 13
Jiaxing 12
Los Angeles 11
Lanzhou 10
Falls Church 9
Hong Kong 9
Lappeenranta 9
Seoul 9
Padova 8
Palermo 7
Tombolo 7
Dongguan 5
Fairfield 5
Florence 5
Fuzhou 5
Washington 5
Amsterdam 4
Ancona 4
Arco 4
Bari 4
Boydton 4
Chicago 4
Delhi 4
Kemerovo 4
Pamplona 4
Riva 4
Sant'Ambrogio di Valpolicella 4
Treviso 4
Bollate 3
Boston 3
Busto Garolfo 3
Cambridge 3
Chions 3
Des Moines 3
Detroit 3
Istanbul 3
Nashville 3
Negrar 3
San Diego 3
Sofia 3
Texas City 3
Turin 3
Abbiategrasso 2
Acquedolci 2
Altopascio 2
Barnet 2
Bratislava 2
Breganze 2
Brescia 2
Bryanston 2
Cagliari 2
Ceranova 2
Chennai 2
Clearwater 2
Cologna Veneta 2
Cortona 2
Dubai 2
Ghent 2
Totale 3.539
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 162
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 87
Periostin: The bone and beyond 83
Fatal asthma; is it still an epidemic? 70
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 66
Omalizumab management beyond clinical trials: the added value of a network model 64
What lies beyond Asthma Control Test: Suggestions for clinical practice 64
Allergic rhinitis: pharmacotherapy in pregnancy and old age 62
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 61
Adverse reaction to local anaesthetics: Is it always allergy? 61
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 61
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 60
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 59
Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis 57
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 57
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 56
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 56
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 56
Biologic Therapy in a Patient with Asthma and Nasal Polyps 54
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 54
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study 53
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 50
Towards precision medicine: The application of omics technologies in asthma management 50
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 50
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma 50
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 50
Asthma management among different specialists: results from a national Italian survey 49
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 48
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 47
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 47
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 47
COPD prevalence in a north-eastern Italian general population 47
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders 47
Occupational rhinitis to sodium alendronate 46
Quality of life in patients with food allergy 46
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 45
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 45
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 45
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 45
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 44
Severe refractory asthma: current treatment options and ongoing research 44
Biologic Therapy in a Patient with Asthma and Nasal Polyps 44
Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study 44
BCG vaccination and COVID-19: Much ado about nothing? 44
Uncontrolled Asthma: Unmet Needs in the Management of Patients 44
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 43
Asthma management among allergists in Italy: results from a survey 43
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 42
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 42
Allergy and Sexual Behaviours: an Update 42
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 42
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 41
Emerging drugs for allergic conjunctivitis 41
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 41
Biologics and global burden of asthma: A worldwide portrait and a call for action 41
Targeting eosinophils: severe asthma and beyond 40
Anaphylaxis and intimate behaviour 40
[Fractional exhaled nitric oxide measurement during specific inhalation challenge tests] 39
Anxiety and Depression Effects During Drug Provocation Test 39
Asthma and anaphylaxis 39
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 39
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 39
Oral health in asthmatic patients: a review 38
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 38
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 37
Biologics for the Treatments of Allergic Conditions 37
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 37
Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for "Omics" Technology? 36
Sex in Respiratory and Skin Allergies 36
Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry 36
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 35
The role of the pharmacy in the management of bronchial asthma: A literature-based evaluation 35
Use of complementary medicine among patients with allergic rhinitis: an Italian nationwide survey. 35
Italian study on buckwheat allergy: prevalence and clinical features of buckwheat-sensitized patients in Italy 35
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 35
Usefulness of basophil activation test in diagnosis of occupational nonasthmatic eosinophilic bronchitis 35
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 34
Vitamin B12 and Atopic Dermatitis: Any Therapeutic Relevance For Oral Supplementation? 34
Type 2 immunity in asthma 33
Prevalence and features of asthma-chronic obstructive pulmonary disease overlap in Northern Italy general population 33
Occupational eosinophilic bronchitis: Considerations and new diagnostic instruments in the margins of a clinical case. [La bronchite eosinofila professionale: Considerazioni e nuovi strumenti diagnostici a margine di un caso clinico] 33
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 33
Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine? 32
Spontaneous pneumomediastinum complicating severe acute asthma exacerbation in adult patients 31
Management of chronic spontaneous urticaria: a worldwide perspective 31
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 31
Safety and tolerability of sublingual immunotherapy in clinical trials and real life 30
Effects of sublingual immunotherapy on allergic inflammation: an update 30
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 30
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response 30
Immune Mechanisms of Allergen-Specific Immunotherapy 29
Respiratory allergies in childhood: Recent advances and future challenges 29
Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address 29
OCCUPATION study (OCCUPationl asthma: a naTIONal based study): a survey on occupational asthma awareness among Italian allergists 29
Minimal clinically important difference for asthma endpoints: an expert consensus report 29
Reconsidering anaphylaxis at the time of COVID-19 pandemic 29
The EAACI-AAAAI-WAO Junior Members' joint survey: A worldwide snapshot of Allergy and Clinical Immunology specialty 27
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-Thalassemia: additional dose role 25
COVID-19 pandemic and environment: Not only air pollution 25
Usefulness of induced sputum in investigating occupational asthma with normal responsiveness to methacholine: a case report 25
Totale 4.440
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.487
article - articoli 27.487
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.974
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020412 29 1 1 4 40 28 8 2 3 153 101 42
2020/2021697 77 125 23 83 144 77 17 23 20 9 45 54
2021/2022714 94 176 15 43 15 14 7 50 50 12 58 180
2022/20231.926 145 138 223 221 217 452 43 106 240 12 80 49
2023/20241.487 57 102 124 196 117 345 110 61 19 62 194 100
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 5.474